Literature DB >> 17637177

Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells.

Xiao-Jia Huang1, Zhen-Qiu Ma, Wei-Ping Zhang, Yun-Bi Lu, Er-Qing Wei.   

Abstract

Artemisinin and its analogue dihydroartemisinin exert cytotoxic effects in some kinds of cancer cell lines. Here we determined whether dihydroartemisinin inhibits the growth and induces apoptosis of rat C6 glioma cells. We found dihydroartemisinin (5-25 microM) inhibited the growth and induced apoptosis of C6 cells in a concentration- and time-dependent manner; however, it was much less toxic to rat primary astrocytes. Dihydroartemisinin (5-25 microM) also increased the generation of reactive oxygen species in C6 cells. These effects of dihydroartemisinin were enhanced by ferrous ions (12.5-100 microM) and reduced by the iron chelator deferoxamine (25-200 microM). Immunoblotting analysis revealed that dihydroartemisinin (5-25 microM) significantly reduced hypoxia- and deferoxamine-induced expression of hypoxia inducible factor-1alpha and its target gene protein, vascular endothelial growth factor, in C6 cells. The results showed that dihydroartemisinin exerts a selective cytotoxic effect on C6 cells by increasing the reactive oxygen species and inhibiting hypoxia inducible factor-1alpha activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637177     DOI: 10.1211/jpp.59.6.0011

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  27 in total

1.  Deferoxamine: emerging, new neuro-protective benefits.

Authors:  Shailendra Kapoor
Journal:  Neurol Sci       Date:  2013-04-23       Impact factor: 3.307

2.  Dihydroartemisinin inhibits indoxyl sulfate (IS)-promoted cell cycle progression in mesangial cells by targeting COX-2/mPGES-1/PGE2 cascade.

Authors:  Harr-Keshauve Mungun; Shuzhen Li; Yue Zhang; Songming Huang; Zhanjun Jia; Guixia Ding; Aihua Zhang
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

3.  Dihydroartemisinin treatment of multiple myeloma cells causes activation of c-Jun leading to cell apoptosis.

Authors:  Yong Wang; Xiaoyuan Xu; Xiaojian Wu; Weibin Chen; Fangmei Huang; Xiaomin Gui
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

4.  Anti-tumor effects of dihydroartemisinin on human osteosarcoma.

Authors:  Ye Ji; Yi-Cai Zhang; Liu-Bao Pei; Li-Li Shi; Jing-Long Yan; Xue-Hua Ma
Journal:  Mol Cell Biochem       Date:  2011-01-14       Impact factor: 3.396

Review 5.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

6.  Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.

Authors:  Hua Chen; Bei Sun; Shuangjia Wang; Shangha Pan; Yue Gao; Xuewei Bai; Dongbo Xue
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-26       Impact factor: 4.553

Review 7.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

8.  Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells.

Authors:  Yoshinobu Odaka; Baoshan Xu; Yan Luo; Tao Shen; Chaowei Shang; Yang Wu; Hongyu Zhou; Shile Huang
Journal:  Carcinogenesis       Date:  2013-08-08       Impact factor: 4.944

9.  Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo.

Authors:  Ji-Hui Du; Hou-De Zhang; Zhen-Jian Ma; Kun-Mei Ji
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-19       Impact factor: 3.333

10.  Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target.

Authors:  Shiming Zhang; Glenn S Gerhard
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.